A new theranostic pair of 99mTc/188Re-labeled peptide radiotracers has recently demonstrated preclinical and clinical PSMA-targeting efficacy in prostate cancer (16), highlighting the potential utility of this theranostic approach. This evidence concerns the gene FOLH1 and prostate carcinoma.